SEP 25, 2015 03:13 PM PDT

New Drug and Native Flora Combat C. difficile

WRITTEN BY: Kerry Evans
Clostridium difficile is a Gram positive, rod-shaped bacterium commonly found in the soil.  However, a small number of people, about 1 in 20, also house C. difficile in their guts. This usually isn’t a problem, but the bacteria can produce toxins that cause severe cases of colitis, diarrhea, and sometimes death. These infections typically occur in cases where the normal gut flora has been depleted by antibiotics, allowing C. difficile to “take over”.   

Since antibiotics often promote C. difficile infections, they aren’t much use in combating these bacteria. This has left researchers searching for other treatment options, and scientists at Stanford University School of Medicine have taken a unique approach.
 
C. difficile infection causes severe colitis and diarrhea.


Instead of searching for a way to kill C. difficile directly, Matthew Bogyo, Ph.D., used a small molecule called ebselen to disarm C. difficile toxins.  These toxins enter the cells lining the gut and induce an inflammatory response, resulting in colitis and diarrhea.  This proinflammatory response also prevents the normal flora from repopulating the gut.  

Bogyo and colleagues showed that ebselen had a direct effect on the activity of C. difficile toxins by incubating purified toxin with or without ebselen, and then injecting the mixtures into mice.  After three days, all of the mice injected with toxin alone died, while the mice injected with the ebselen and toxin mixture survived.  Bogyo then tested a more clinically relevant model of infection.  They first treated mice with antibiotics to mimic the conditions under which C. difficile infections occur.  Following antibiotic treatment, they infected mice with a highly virulent, drug-resistant strain of C. difficile, and treated them orally with ebselen.  The mice treated with ebselen survived the infection with little evidence of damage to the colon.  

Thus, ebselen both prevented damaging colitis and diarrhea, and allowed the normal flora to outcompete C. difficile.  What’s more, ebselen has already been tested in clinical trials to treat hearing loss in chemotherapy patients.  This means ebselen could be on the fast track to treating C. difficile infections.  

Ebselen isn’t the only unique approach to treating C. difficile. Fecal transplant, as explained in this video, has been highly successful in treating C. difficile infections.  

Sources: Science Daily, Science Translational Medicine, Wikipedia, Cleveland Clinic
 
About the Author
  • Kerry received a doctorate in microbiology from the University of Arkansas for Medical Sciences.
You May Also Like
JAN 19, 2020
Microbiology
JAN 19, 2020
Scientists Find the Limits of Life in an Extreme Environment
Different forms of microbes have been able to make a home even in the harshest conditions. But there are still locations where they can't live....
JAN 19, 2020
Clinical & Molecular DX
JAN 19, 2020
Genetic platform takes the guesswork out of catching infections
A physician is faced with 3 patients: an elderly person with a chronic cough, a child being wheeled out of surgery and a young mother with a high fever. Ho...
JAN 19, 2020
Microbiology
JAN 19, 2020
Measles Outbreaks Strike Samoa, DRC
The largest measles outbreak in the world is now occurring in the Democratic Republic of Congo. Over 5,000 people have died from the illness....
JAN 19, 2020
Microbiology
JAN 19, 2020
Some Antacids Appear to Increase the Risk of Gastroenteritis
Proton pump inhibitors (PPIs) are drugs for heartburn relief; they can reduce stomach acid levels....
JAN 19, 2020
Microbiology
JAN 19, 2020
Potential Therapeutics for Nipah Virus Are Identified
The fatality rate of Nipah virus has an estimated range of 40 to 75 percent...
JAN 19, 2020
Neuroscience
JAN 19, 2020
Are Migraines Caused by Unhealthy Gut Bacteria?
Research is increasingly pointing towards the importance of the gut-brain axis in regulating our health. Not only has the health of our gut bacteria, or mi...
Loading Comments...